Par Pharmaceutical, Inc. Q4 Profit Tops Estimates on Strong Sales
Reuters -- Generic drugmaker Par Pharmaceutical Cos Inc posted a quarterly profit that handily beat market estimates on strong revenue boosted by limited competition on certain generic drugs and three new drug launches.